|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boyle P and Langman JS: ABC of colorectal
cancer: Epidemiology. BMJ. 321:805–808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glade MJ: Food, nutrition, and the
prevention of cancer: a global perspective. American Institute for
Cancer Research/World Cancer Research Fund, American Institute for
Cancer Research, 1997. Nutrition. 15:523–526. 1999.PubMed/NCBI
|
|
4
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Y, Suh Y-A, Fuller MY, Jackson JG,
Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK and
Lozano G: Restoring expression of wild-type p53 suppresses tumor
growth but does not cause tumor regression in mice with a p53
missense mutation. J Clin Invest. 121:893–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Creighton CJ, Gibbons DL and Kurie JM: The
role of epithelial-mesenchymal transition programming in invasion
and metastasis: A clinical perspective. Cancer Manag Res.
5:187–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheppard D: Epithelial-mesenchymal
interactions in fibrosis and repair. Transforming growth factor-β
activation by epithelial cells and fibroblasts. Ann Am Thorac Soc.
12:(Suppl 1). S21–S23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kovacic JC, Mercader N, Torres M, Boehm M
and Fuster V: Epithelial-to-mesenchymal and
endothelial-to-mesenchymal transition: From cardiovascular
development to disease. Circulation. 125:1795–1808. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fraga CH, True LD and Kirk D: Enhanced
expression of the mesenchymal marker, vimentin, in hyperplastic
versus normal human prostatic epithelium. J Urol. 159:270–274.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang L, Lai YK, Zhang J, Wang H, Lin MC,
He ML and Kung HF: Targeting S100P inhibits colon cancer growth and
metastasis by lentivirus-mediated RNA interference and proteomic
analysis. Mol Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang L, Chen Y, Chan CY, Wang X, Lin L,
He ML, Lin MC, Yew DT, Sung JJ, Li JC, et al: Down-regulation of
stathmin is required for TGF-beta inducible early gene 1 induced
growth inhibition of pancreatic cancer cells. Cancer Lett.
274:101–108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peacock O, Lee AC, Cameron F, Tarbox R,
Vafadar-Isfahani N, Tufarelli C and Lund JN: Inflammation and
MiR-21 pathways functionally interact to downregulate PDCD4 in
colorectal cancer. PLoS One. 9:e1102672014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Fei B, Wang Q, Song M, Yin Y,
Zhang B, Ni S, Guo W, Bian Z, Quan C, et al: MicroRNA-638 inhibits
cell proliferation, invasion and regulates cell cycle by targeting
tetraspanin 1 in human colorectal carcinoma. Oncotarget.
5:12083–12096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Paris PL, Chen J, Ngo V, Yao H,
Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next
generation sequencing of pancreatic cyst fluid microRNAs from low
grade-benign and high grade-invasive lesions. Cancer Lett.
356:404–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stahlhut C and Slack FJ: MicroRNAs and the
cancer phenotype: Profiling, signatures and clinical implications.
Genome Med. 5:1112013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Friedman RC, Farh KK-H, Burge CB and
Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs.
Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christofori G: New signals from the
invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berx G, Raspé E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schipper JH, Frixen UH, Behrens J, Unger
A, Jahnke K and Birchmeier W: E-cadherin expression in squamous
cell carcinomas of head and neck: Inverse correlation with tumor
dedifferentiation and lymph node metastasis. Cancer Res.
51:6328–6337. 1991.PubMed/NCBI
|
|
26
|
Oka H, Shiozaki H, Kobayashi K, Inoue M,
Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S,
Takeichi M, et al: Expression of E-cadherin cell adhesion molecules
in human breast cancer tissues and its relationship to metastasis.
Cancer Res. 53:1696–1701. 1993.PubMed/NCBI
|
|
27
|
Perl A-K, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vleminckx K, Vakaet L Jr, Mareel M, Fiers
W and van Roy F: Genetic manipulation of E-cadherin expression by
epithelial tumor cells reveals an invasion suppressor role. Cell.
66:107–119. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frixen UH, Behrens J, Sachs M, Eberle G,
Voss B, Warda A, Löchner D and Birchmeier W: E-cadherin-mediated
cell-cell adhesion prevents invasiveness of human carcinoma cells.
J Cell Biol. 113:173–185. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gumbiner BM: Regulation of
cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol.
6:622–634. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ivaska J, Vuoriluoto K, Huovinen T, Izawa
I, Inagaki M and Parker PJ: PKCepsilon-mediated phosphorylation of
vimentin controls integrin recycling and motility. EMBO J.
24:3834–3845. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
